Respected Scientific Leader Brings 30 Years of Biotechnology
Experience to New Role
SOUTH
RIDING, Va., June 20,
2024 /PRNewswire-PRWeb/ -- Slone Partners, a
nationwide executive search firm for life sciences and healthcare
organizations, has announced the placement of Kurt Gish Ph.D., as
Chief Scientific Officer at BioLoomics, a biotechnology company
that targets peptide-antibody chimeras to specific compartments
inside of diseased cells. Dr Gish will focus on building the
company's pipeline of lysosomal targeting ADCs in oncology to
overcome the limitations of poor tumor uptake, which hinders safety
and efficacy across the ADC market.
"Kurt Gish
is a tremendously talented and highly respected scientist and
business leader with a history of driving the development of
innovative therapies and treatments," said Leslie Loveless, CEO and Managing Partner at
Slone Partners.
Prior to BioLoomics, Dr. Gish served as Chief Scientific Officer
and Founder of Trilo Therapeutics where he pioneered a novel DNA
encoded library approach to build D-peptide conjugates to rival
traditional ADC modalities. Prior to Trilo, Dr. Gish was an early
pioneer in ADCs at AbbVie, investigating novel linkers and
payloads, exploring the nature of antigen-independent toxicity and
driving two ADC programs into human clinical trials. He serves on
the scientific advisory board of the Myeloma Investment Fund of the
Multiple Myeloma Research Foundation.
"Kurt Gish is a tremendously
talented and highly respected scientist and business leader with a
history of driving the development of innovative therapies and
treatments," said Leslie Loveless,
CEO and Managing Partner at Slone Partners. "As BioLoomis continues
seeking new solutions to unlock the many mysteries of cancer, Dr.
Gish will play an important role as part of the company's
leadership team."
"Kurt is an impressive and accomplished scientist who sits at
the intersection of ADCs, peptides, and target
discovery/validation. He has a deep understanding of how improper
spatial targeting of ADCs has limited the field," said Doug Chapnick, Founder and CEO of BioLoomis.
"With his deep experience in the ADC space, I am confident that
Kurt will be invaluable to advancing BioLoomics's technology to
build safer and more efficacious ADCs for both strategic partners
and internal programs."
"BioLoomics is developing incredible technology to deliver more
therapeutic drugs directly into cancer cells while minimizing
systemic toxicity," remarked Dr. Gish. "I'm thrilled to join such
an innovative team and look forward to getting the best possible
treatments to patients who so desperately need them."
Dr. Gish earned his Ph.D. in Biology from Stanford University and studied molecular
immunology during his postdoctoral fellowship at the DNAX Research
Institute.
ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is a premier executive search firm
that delivers visionary leaders who build amazing life sciences and
healthcare organizations. With a nationwide presence in the most
active industry hubs, we specialize in discovering and placing
world-class Board, C-Suite leadership, and upper management talent
with experience, conviction, and cultural competence in emerging
and well-established companies. Our portfolio of executive search
and advisory services includes customized cultural solutions
through strategic planning, education, training, and coaching.
Slone Partners proudly holds the designation as a Certified LGBT
Business Enterprise™ by the National Gay & Lesbian Chamber of
Commerce (NGLCC) and has earned recognition as a Top Executive
Search Firm and a Top 20 Diversity and Inclusion Services firm by
Manage HR. To learn more about Slone Partners' value proposition
and processes, visit https://www.slonepartners.com or call
888.784.3422.
ABOUT BIOLOOMICS
Headquartered in Colorado,
BioLoomics is a preclinical stage biotechnology company pioneering
directed evolution of antibody-peptide chimeras with programmable
cell entry and lysosome targeting. Lysosome targeted
antibody-peptide chimeras have broad utility to elicit increased
payload delivery mechanisms in the ADC therapeutic space, as well
as target degradation in the biologics therapeutic space. The
company has raised a total of $10.1
million from top investors including Innovations Endeavors,
Horizons Ventures, TechU Ventures, Boom Capital Ventures, BoxOne
Ventures, GC&H, and Viswa Colluru.
Media Contact
Doug Gavel, Doug Gavel
Communications, (617) 429-4417, doug.gavel@gmail.com,
www.douggavel.com
View original content to download
multimedia:https://www.prweb.com/releases/slone-partners-places-kurt-gish-as-chief-scientific-officer-at-bioloomics-302176591.html
SOURCE BioLoomics